Get the Stockscreener App
4.99
4.95%
-0.26
Foghorn Therapeutics Inc stock is traded at $4.99, with a volume of 171.66K.
It is down -4.95% in the last 24 hours and up +2.46% over the past month.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
See More
Previous Close:
$5.25
Open:
$5.13
24h Volume:
171.66K
Relative Volume:
1.32
Market Cap:
$278.15M
Revenue:
$34.16M
Net Income/Loss:
$-98.43M
P/E Ratio:
-2.1325
EPS:
-2.34
Net Cash Flow:
$-119.33M
1W Performance:
-19.39%
1M Performance:
+2.46%
6M Performance:
+19.09%
1Y Performance:
-23.35%
1-Day Range:
$4.9272
$5.25
1-Week Range:
$4.9272
$6.7899
52-Week Range:
$2.9448
$10.25
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Name
Foghorn Therapeutics Inc
Sector
Industry
Phone
617-586-3100
Address
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.99 | 292.64M | 34.16M | -98.43M | -119.33M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jan-30-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-24 | Initiated | Jefferies | Buy |
| Aug-19-24 | Initiated | Evercore ISI | Outperform |
| Mar-28-23 | Initiated | BofA Securities | Buy |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-22-21 | Initiated | H.C. Wainwright | Buy |
| Nov-17-20 | Initiated | Cowen | Outperform |
| Nov-17-20 | Initiated | Goldman | Buy |
| Nov-17-20 | Initiated | Morgan Stanley | Overweight |
| Nov-17-20 | Initiated | Wedbush | Outperform |
View All
Foghorn Therapeutics Inc Stock (FHTX) Latest News
Real time alert setup for Foghorn Therapeutics Inc. performanceShort Term Profit Strategy with Entry Cues - Newser
Is Foghorn Therapeutics Inc. meeting your algorithmic filter criteriaCapital Secure Pattern Signal Analysis Sheet - Newser
How to recover losses in Foghorn Therapeutics Inc. stockFree Intraday Trend Analysis for Fast Gains - Newser
Is Foghorn Therapeutics Inc. trending in predictive chart modelsNear-Term Market Opportunity Forecast Sheet - Newser
Comparing Foghorn Therapeutics Inc. in custom built stock radarsStock Market Trend and Pattern Analysis - Newser
What makes Foghorn Therapeutics Inc. stock price move sharplyFree Real Time Stock Movement Analysis - Newser
How does Foghorn Therapeutics Inc. generate profit in a changing economyPre Market Picks With High Returns - jammulinksnews.com
Foghorn Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Liquidity and Price Flow Analysis - Newser
Foghorn Therapeutics Faces Significant Business Risk: Potential Impact on Operations and Investor Confidence - TipRanks
Using data models to predict Foghorn Therapeutics Inc. stock movementRisk-Managed Strategy Based on Price Analysis - Newser
How Foghorn Therapeutics Inc. stock performs during market volatilityPredictive Screener for Daily Trade Watch - Newser
Why Foghorn Therapeutics Inc. stock attracts strong analyst attentionTrade Setup Builder with Custom Alerts - Newser
Does Foghorn Therapeutics Inc. stock perform well during market downturnsAdvanced Screener Guidance With High Returns - jammulinksnews.com
How many analysts rate Foghorn Therapeutics Inc. as a “Buy”Wealth Building Watchlist For Every Investor - jammulinksnews.com
Foghorn Therapeutics Inc. stock prediction for this weekEarnings Report Summary with Market Impact - Newser
Foghorn Therapeutics Inc.’s Price Action Aligns with Quant SignalsRisk Adjusted Technical Entry Plan Gains Followers - metal.it
Foghorn Therapeutics Inc. Recovery Likely Here’s What Data ShowsReal Trader Watchlist of Hot Stocks Released - metal.it
Traders Consider Averaging Down in Foghorn Therapeutics Inc.Investment Playbook for Growing Markets Shared - beatles.ru
Top Risks to Consider Before Buying Foghorn Therapeutics Inc. StockSector Rotation Strategy for Smart Traders - Newser
What are the technical indicators suggesting about Foghorn Therapeutics Inc.Financial News Forecasts For Smart Trading - jammulinksnews.com
Is it the right time to buy Foghorn Therapeutics Inc. stockAchieve rapid financial growth with expert picks - jammulinksnews.com
How to recover losses in Foghorn Therapeutics Inc. stock Weekly Setup Summary for Risk Controlled Trades - Newser
Is Foghorn Therapeutics Inc. a growth stock or a value stockInvest in stocks with strong fundamentals - jammulinksnews.com
Is Foghorn Therapeutics Inc. stock overvalued or undervaluedBuild wealth with high-performing stocks - jammulinksnews.com
What is Foghorn Therapeutics Inc. company’s growth strategyCapitalize on market trends with confidence - jammulinksnews.com
What are the latest earnings results for Foghorn Therapeutics Inc.Breakneck growth rates - jammulinksnews.com
Should I hold or sell Foghorn Therapeutics Inc. stock in 2025Build capital through low-risk investments - jammulinksnews.com
How strong is Foghorn Therapeutics Inc. company’s balance sheetExtraordinary earning power - jammulinksnews.com
Foghorn Therapeutics Inc Stock (FHTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):